Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0432222 (
SEM
)
47,337
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Muscarinic acetylcholine receptors (mAChRs) mediate their main cardiac effects via
pertussis
toxin-sensitive G-proteins. Physiological effects differ considerably between atrium and ventricle, and it is unknown to which extent these differences derive from selective receptor-G-protein coupling or further downstream events. We have characterized specific coupling between mAChRs and Gi/Go-protein isoforms in atrial and ventricular myocardium by agonist-dependent photoaffinity labeling with [(32)P]azidoanilido GTP (aaGTP) and immunoprecipitation in sarcolemmal membranes from terminally failing human hearts. The total amount of mAChRs, as determined by specific binding of [(3)H]QNB, was significantly higher in right-atrial (RA +/-
SEM
, 959 +/- 68 fmol/mg, n = 4) than in left-ventricular membranes (LV, 582 +/- 53 fmol/mg, n = 6). Standardized immunoblots revealed that Gialpha-2 was the predominant subtype in both regions. A 40-kDa splice variant of Goalpha (Goalpha-1 and/or Goalpha-3) was almost exclusively detectable in RA. Levels of Gialpha-3 and a 39-kDa splice variant of Goalpha (Goalpha-2) were also higher in RA. Basal aaGTP binding was higher in RA than in LV for all Gialpha/Goalpha subtypes. The carbachol (10 micromol/l)-induced increase in aaGTP binding was significantly higher in RA than in LV for Goalpha-1/3 (336 +/- 95% of LV, n = 4) and for Gialpha-3 (211 +/- 83%), lower for Gialpha-2 (42 +/- 5%), and was similar in both regions for Goalpha-2 (130 +/- 62%). The differential coupling of mAChRs in human RA and LV suggests that the initiation of different physiological responses to mAChR stimulation starts with signal sorting at the receptor-G-protein level.
...
PMID:Differential coupling of m-cholinoceptors to Gi/Go-proteins in failing human myocardium. 1451 34
Mast cells' hyperplasia and activation are prominent features in Trichinella spiralis infection. Recently, it was shown that TSL-1 antigens from T. spiralis muscle larvae induce IL-4 and TNF release by unsensitized, normal mast cells (MC) involving an Ig-independent mechanism. In this study, we characterized histamine secretion induced by TSL-1 antigens from normal, unsensitized rat peritoneal MC. Maximum histamine secretion (30+/-5.3%
SEM
, n=13) was achieved with 30 ng/mL TSL-1 antigens. However, TSL-1 did not induce an increase in beta-hexosaminidase release or NADPH oxidase activity by MC. Interestingly, histamine secretion by TSL-1 was completed at 10s, and was inhibited by both Bordetella
pertussis
toxin and neuraminidase V, characteristics similar to those involved in substance P-induced histamine secretion. However, in contrast to substance P, TSL-1 induced histamine secretion in the absence of detectable changes in intracellular Ca(2+). We are investigating the molecular pathways involved in MC activation by TSL-1.
...
PMID:Trichinella spiralis: histamine secretion induced by TSL-1 antigens from unsensitized mast cells. 1660 Feb 18
In previous studies, we demonstrated biphasic purinergic effects on prolactin (PRL) secretion stimulated by an adenosine A2 agonist. In the present study, we investigated the role of the activation of adenosine A1 receptors by (R)-N6-(2-phenylisopropyl)adenosine (R-PIA) at the pituitary level in in vitro PRL secretion. Hemipituitaries (one per cuvette in five replicates) from adult male rats were incubated. Administration of R-PIA (0.001, 0.01, 0.1, 1, and 10 microM) induced a reduction of PRL secretion into the medium in a U-shaped dose-response curve. The maximal reduction was obtained with 0.1 microM R-PIA (mean +/-
SEM
, 36.01 +/- 5.53 ng/mg tissue weight (t.w.)) treatment compared to control (264.56 +/- 15.46 ng/mg t.w.). R-PIA inhibition (0.01 microM = 141.97 +/- 15.79 vs control = 244.77 +/- 13.79 ng/mg t.w.) of PRL release was blocked by 1 microM cyclopentyltheophylline, a specific A1 receptor antagonist (1 microM = 212.360 +/- 26.560 ng/mg t.w.), whereas cyclopentyltheophylline alone (0.01, 0.1, 1 microM) had no effect. R-PIA (0.001, 0.01, 0.1, 1 microM) produced inhibition of PRL secretion stimulated by both phospholipase C (0.5 IU/mL; 977.44 +/- 76.17 ng/mg t.w.) and dibutyryl cAMP (1 mM; 415.93 +/- 37.66 ng/mg t.w.) with nadir established at the dose of 0.1 microM (225.55 +/- 71.42 and 201.9 +/- 19.08 ng/mg t.w., respectively). Similarly, R-PIA (0.01 microM) decreased (242.00 +/- 24.00 ng/mg t.w.) the PRL secretion stimulated by cholera toxin (0.5 mg/mL; 1050.00 +/- 70.00 ng/mg t.w.). In contrast, R-PIA had no effect (468.00 +/- 34.00 ng/mg t.w.) on PRL secretion stimulation by
pertussis
toxin (0.5 mg/mL; 430.00 +/- 26.00 ng/mg t.w.). These results suggest that inhibition of PRL secretion after A1 receptor activation by R-PIA is mediated by a Gi protein-dependent mechanism.
...
PMID:Adenosine A1 receptor-mediated inhibition of in vitro prolactin secretion from the rat anterior pituitary. 1714 62
<< Previous
1
2
3
4